Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

	Edgar Filing: II	NIERLEUKIN GENETICS IN	C - Form 4	
INTERLEUKIN GENETICS Form 4 August 02, 2016	S INC			
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pu	W MENT OF CHA ursuant to Section (a) of the Public	JRITIES AND EXCHANGE (ashington, D.C. 20549 NGES IN BENEFICIAL OW SECURITIES 16(a) of the Securities Exchang Utility Holding Company Act of Investment Company Act of 194	NERSHIP OF ge Act of 1934, of 1935 or Section	OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5
1. Name and Address of Reporting KOLLURI KRISHNA KIT	ΓU Symbo	RLEUKIN GENETICS INC	Issuer	eporting Person(s) to all applicable)
(Last) (First) 1954 GREENSPRING DRIVE, SUITE 600		e of Earliest Transaction n/Day/Year) /2016	Director Officer (give titl below)	X 10% Owner le Other (specify below)
(Street)		mendment, Date Original /onth/Day/Year)	Applicable Line) _X_ Form filed by One	
TIMONIUM, MD 21093			Form filed by Mor Person	e than One Reporting
(City) (State)	(Zip) Ta	able I - Non-Derivative Securities Acc	quired, Disposed of, o	or Beneficially Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		Code (Instr. 3, 4 and 5) (Instr. 8) (A) or) or 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownershipof IndirectForm:BeneficialDirect (D)Ownershipor Indirect(Instr. 4)(I)(Instr. 4)
Common 07/29/2016 Stock		P 20 120 724 A \$	55,418,811	I See Note $1 \frac{(1)}{2}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amou 2 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securi Securities Acquired (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Price of (Month/Day/Year) (A) or Disposed of (Instr. 3) (Instr. 8) Derivative (D) Security (Instr. 3, 4, and 5) Date Expiration Title Exercisable Date (D) Code V (A) Common Stock Common 07/29/2016 07/29/2023 Warrant 07/29/2016 Ρ \$ 0.0994 20,120,724

Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

Reporting Owners

(right to buy)

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KOLLURI KRISHNA KITTU 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM, MD 21093		Х		
Signatures				
/s/ Sasha Keough, attorney-in-fact	08/02/2016			
**Signature of Reporting Person		Date		

Explanation of Responses:

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Reporting Person is a Director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 is the sole member of Growth

(1) Equity Opportunities Fund III, LLC ("GEO"), the direct beneficial owner of the Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Shares held by GEO, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Amo

Nun

Shar

20,

Stock